Is the Combination of Immunotherapy and Radiotherapy in Non-small Cell Lung Cancer a Feasible and Effective Approach?
Authors:
Open Access
- 7 November 2019
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 6, 244
Abstract
For many years, conventional oncologic treatments such as surgery, chemotherapy, and radiotherapy (RT) have dominated the field of non-small-cell lung cancer (NSCLC). The recent introduction of immunotherapy (IT) in clinical practice, especially strategies targeting negative regulators of the immune system, so-called immune checkpoint inhibitors, has led to a paradigm shift in lung cancer as in many other solid tumors. Although antibodies against programmed death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) are currently on the forefront of the immuno-oncology field, the first efforts to eradicate cancer by exploiting the host's immune system date back to several decades ago. Even then, researchers aimed to explore the addition of RT to IT strategies in NSCLC patients, attributing its potential benefit to local control of target lesions through direct and indirect DNA damage in cancer cells. However, recent pre-clinical and clinical data have shown RT may also modify antitumor immune responses through induction of immunogenic cell death and reprogramming of the tumor microenvironment. This has led many to reexamine RT as a partner therapy to immuno-oncology treatments and investigate their potential synergy in an exponentially growing number of clinical trials. Herein, the authors review the rationale of combining IT and RT across all NSCLC disease stages and summarize both historical and current clinical evidence surrounding these combination strategies. Furthermore, an overview is provided of active clinical trials exploring the IT-RT concept in different settings of NSCLC.Keywords
This publication has 107 references indexed in Scilit:
- The convergence of radiation and immunogenic cell death signaling pathwaysFrontiers in Oncology, 2012
- Radiation Enhances Regulatory T Cell RepresentationInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II TrialClinical Cancer Research, 2011
- Resistance of CD45RA− T Cells to Apoptosis and Functional Impairment, and Activation of Tumor-Antigen Specific T Cells during Radiation Therapy of Prostate CancerThe Journal of Immunology, 2010
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatmentBlood, 2009
- T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation TherapyClinical Cancer Research, 2008
- Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiationExperimental & Molecular Medicine, 2006
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Adjuvant immunotherapy by levamisole in resectable lung cancer: A control studyEuropean Journal of Cancer (1965), 1980